|
|
|
| Real-world study of the efficacy and safety of Carrelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer#br# |
| ZHU Lusha1 WANG Songhua2 LI Jindong1▲ |
1.Department of Scientific Research, Taizhou People’s Hospital, Jiangsu Province, Taizhou 225300, China;
2.Department of Oncology, Taizhou People’s Hospital, Jiangsu Province, Taizhou 225300, China |
|
|
|
Abstract Objective To explore the real-world study of the efficacy and safety of Carrelizumab in the treatment of advanced non-small cell lung cancer. Methods A total of 62 patients with advanced non-small cell lung cancer treated with Carrelizumab from March 2019 to March 2020 who admitted to the Taizhou People’s Hospital of Jiangsu Province were selected, and according to the wishes of patients, they were divided into single-drug group (Carrelizumab, 41 cases) and combination group (Carrelizumab combined with chemotherapy regimen, 21 cases). After three cycles of treatment, the clinical efficacy of two groups were compared, adverse drug reactions of two groups were observed, and progression-free survival and median survival time of two groups was observed after 12 months of follow up. Results The total effective rate of combination group was higher than that of single-drug group (P < 0.05). There was no statistically significant difference in the total incidence of adverse reactions between two groups (P > 0.05). Progression-free survival rate and median survival time between two groups were statistically significant (P < 0.05). Conclusion Carrelizumab has a good effect in the treatment of advanced non-small cell lung cancer in real-world study, and the combined treatment effect is better.
|
|
|
|
|
|
[1] Duma N，Santana-Davila R，Molina JR. Non-Small Cell Lung Cancer：Epidemiology，Screening，Diagnosis，and Treatment [J]. Mayo Clin Proc，2019，94（8）：1623-1640.
[2] 张莉，易成凤，何源，等.化疗周期对埃克替尼一二线化疗耐药的表皮生长因子受体突变不明的非小细胞肺癌临床疗效分析[J].中华肺部疾病杂志：电子版，2019，12（5）：79-82.
[3] Arbour KC，Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer：A Review [J]. JAMA，2019，322（8）：764-774.
[4] Reck M，Borghaei H，O’Byrne KJ. Nivolumab plus ipilimumab in non-small-cell lung cancer [J]. Future Oncol，2019，15（19）：2287-2302.
[5] 李文洁，金发光，袁灿亮，等.同步推量调强放疗联合靶向药物治疗晚期非小细胞肺癌的临床效果[J].中华肺部疾病杂志：电子版，2020，13（4）：507-509.
[6] Broderick SR. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer [J]. Thorac Surg Clin，2020， 30（2）：215-220.
[7] Hsu ML，Naidoo J. Principles of Immunotherapy in Non-Small Cell Lung Cancer [J]. Thorac Surg Clin，2020，30（2）：187-198.
[8] Judd J，Borghaei H. Combining Immunotherapy and Chem-otherapy for Non-Small Cell Lung Cancer [J]. Thorac Surg Clin，2020，30（2）：199-206.
[9] Yan Z，Yao ZH，Yao SN，et al. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma [J]. Immunotherapy，2020，12（16）：1161-1166.
[10] Markham A，Keam SJ. Camrelizumab：First Global Approval [J]. Drugs，2019，79（12）：1355-1361.
[11] 薛朝军，余克富，靳会欣，等.5种程序性细胞死亡蛋白1抑制剂的Mini卫生技术评估[J].中国医院药学杂志，2020，40（15）：41-45，65.
[12] 王书航，王洁.2018年V3版NCCN非小细胞肺癌指南更新要点解读[J].华西医学，2018，33（4）：388-392.
[13] 张百红，岳红云.实体瘤疗效评价标准简介[J].国际肿瘤学杂志，2016，43（11）：845-847.
[14] Uras IZ，Moll HP，Casanova E. Targeting KRAS Mutant Non-Small-Cell Lung Cancer：Past，Present and Future [J]. Int J Mol Sci，2020，21（12）：4325-4332.
[15] Yang CY，Yang JC，Yang PC. Precision Management of Advanced Non-Small Cell Lung Cancer [J]. Annu Rev Med，2020，71（5）：117-136.
[16] 尤静，杨丹，李东明，等.同步推量调强放疗在局部晚期非小细胞肺癌中的应用[J].中国肺癌杂志，2019，22（11）：22-27.
[17] 祝情情，谢超，宋宝，等.节拍化疗在晚期非小细胞肺癌治疗中的应用[J].国际肿瘤学杂志，2019，46（6）：374-377.
[18] 张艳萍.阿帕替尼对晚期非小细胞肺癌疗效和安全性的Meta分析[D].合肥：安徽医科大学，2019.
[19] 贺庆，高华，王军志.肿瘤免疫治疗相关PD-1分子表达的调节因素分析[J].中国新药杂志，2020，25（13）：1478-1484.
[20] 闫睿.化疗与靶向治疗顺序对晚期进展性非小细胞肺癌患者进展及生存期的影响[J].中国现代医生，2021，59（1）：73-76.
[21] 金倩晨，姜佳宁，吕金燕，等.阿特珠单抗、贝伐珠单抗联合化疗治疗EGFR-TKIs耐药后晚期非小细胞肺癌1例并文献复习[J].中国医药科学，2021，11（4）：239-241.
[22] 陈轩，李真斌，易向军.多西他赛联合安罗替尼二线治疗晚期非小细胞肺癌的有效性及安全性分析[J].中国当代医药，2021，28（11）：109-111，127.
[23] Liu J，Liu Q，Li Y，et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer：an open-label phase Ⅱ trial [J]. J Immunother Cancer，2020，8（1）：696-703.
[24] 曾志艳，李庆艳，屈雪玲，等.卡瑞利珠单抗致乳腺反应性毛细血管瘤1例[J].中国肿瘤临床，2021，48（13）：701-702.
[25] Lickliter JD，Gan HK，Voskoboynik M，et al. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia [J]. Drug Des Devel Ther，2020，14（8）：1177-1189.
[26] 位变，王华庆，柳凤亭，等.PD-1抑制剂卡瑞利珠单抗治疗恶性肿瘤引发反应性皮肤毛细血管增生二例[J].中华皮肤科杂志，2021，54（3）：252-253.
[27] 刘金，曹刚，张根山，等.卡瑞利珠单抗联合阿帕替尼治疗D-TACE后进展的中晚期肝癌的初步疗效及安全性分析[J].中华医学杂志，2021，101（29）：2304-2309.
[28] Zhou CC，Gao GH，Wu FY，et al. A phase Ⅰb study of SHR-1210 plus apatinib for heavily previously treated advanced non-squamous non-small cell lung cancer （NSCLC） patients [J]. J Clin Oncol，2018，36（15）：2101-2107.
[29] 袁国盛，何伟猛，胡晓云，等.卡瑞利珠单克隆抗体联合阿帕替尼二线治疗不可切除肝细胞癌的临床疗效及安全性分析：一项多中心回顾性研究[J].中华肝脏病杂志，2021，29（4）：326-331. |
|
|
|
